6USZ
Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
Summary for 6USZ
Entry DOI | 10.2210/pdb6usz/pdb |
Related | 6USX 6UT0 |
Descriptor | GTPase KRas, GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, ... (5 entities in total) |
Functional Keywords | hydrolase inhibitor, hydrolase, hydrolase-inhibitor complex, hydrolase/inhibitor |
Biological source | Homo sapiens (Human) |
Total number of polymer chains | 1 |
Total formula weight | 20373.99 |
Authors | Vigers, G.P.,Smith, D.J. (deposition date: 2019-10-28, release date: 2020-04-22, Last modification date: 2023-10-11) |
Primary citation | Fell, J.B.,Fischer, J.P.,Baer, B.R.,Blake, J.F.,Bouhana, K.,Briere, D.M.,Brown, K.D.,Burgess, L.E.,Burns, A.C.,Burkard, M.R.,Chiang, H.,Chicarelli, M.J.,Cook, A.W.,Gaudino, J.J.,Hallin, J.,Hanson, L.,Hartley, D.P.,Hicken, E.J.,Hingorani, G.P.,Hinklin, R.J.,Mejia, M.J.,Olson, P.,Otten, J.N.,Rhodes, S.P.,Rodriguez, M.E.,Savechenkov, P.,Smith, D.J.,Sudhakar, N.,Sullivan, F.X.,Tang, T.P.,Vigers, G.P.,Wollenberg, L.,Christensen, J.G.,Marx, M.A. Identification of the Clinical Development CandidateMRTX849, a Covalent KRASG12CInhibitor for the Treatment of Cancer. J.Med.Chem., 63:6679-6693, 2020 Cited by PubMed: 32250617DOI: 10.1021/acs.jmedchem.9b02052 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.03 Å) |
Structure validation
Download full validation report